News1 min ago
Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
LUND, Sweden, May 30, 2023 /PRNewswire/ — Hansa Biopharma (“Hansa”), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been...
